OPK vs. PCRX, AVIR, ADCT, TARO, HRMY, FOLD, NVAX, GERN, CLDX, and MYGN
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Pacira BioSciences (PCRX), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Taro Pharmaceutical Industries (TARO), Harmony Biosciences (HRMY), Amicus Therapeutics (FOLD), Novavax (NVAX), Geron (GERN), Celldex Therapeutics (CLDX), and Myriad Genetics (MYGN). These companies are all part of the "medical" sector.
OPKO Health (NASDAQ:OPK) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership.
Pacira BioSciences has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 47.3% of OPKO Health shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
OPKO Health currently has a consensus target price of $3.17, indicating a potential upside of 151.32%. Pacira BioSciences has a consensus target price of $47.40, indicating a potential upside of 70.38%. Given OPKO Health's higher probable upside, research analysts clearly believe OPKO Health is more favorable than Pacira BioSciences.
In the previous week, Pacira BioSciences had 4 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Pacira BioSciences and 2 mentions for OPKO Health. Pacira BioSciences' average media sentiment score of 1.25 beat OPKO Health's score of 0.51 indicating that Pacira BioSciences is being referred to more favorably in the news media.
OPKO Health has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Pacira BioSciences received 312 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.81% of users gave Pacira BioSciences an outperform vote while only 65.61% of users gave OPKO Health an outperform vote.
Pacira BioSciences has a net margin of 10.34% compared to OPKO Health's net margin of -31.44%. Pacira BioSciences' return on equity of 12.98% beat OPKO Health's return on equity.
Summary
Pacira BioSciences beats OPKO Health on 13 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
